which I morning’s were recent fourth On update for quarter. fourth Dan. on COVID-XX impacts of Thanks, guidance. call, quarter this from million the quarter Revenues an walk year's fiscal and prior our XXXX provide approximately review billion results, the through roughly on $XXX $X.X the our will our business
$XXX.X compared last prior charge year’s quarter credit partially million Net the was loss net to our LIFO in offset the $X.XX in current increase $X in mostly The is the tax a $XXX.X or loss $X.XX quarter. in share due by year to for million LIFO to $XX.X year. per per diluted of fourth billion higher expense million income share diluted or compared the a
the charge is it most on The our deferred recent increase taxable valuation will million $XXX.X against be net deferred relating the by the impacted net valuation was that realize assessment benefit generated than negatively to increase sufficient more tax was asset. asset. to our likely the to allowance not, that based allowance not income expense in tax tax of Income an
loss the partially in the or $XXX.X sale the net assets is the million which current year to This prior-year the net in $XX.X compared to $X.XX of or Adjusted quarter share an receivable $XXX.X in primarily net quarter. was prior-year diluted in $X.XX gain of and versus million in current sale due a was $XX.X our in million on of XXXX loss the adjusted loss The adjusted prior-year loss per was diluted current compared share increase adjusted our quarter in quarter. quarter. fourth by to a million offset EBITDA increase CMS per
segment pharmacy the billion, quarter for revenue year's than higher $X which last fourth was Retail the $XX was million quarter.
pharmacy since revenue in by of increase points the basis count XXXX. retail increase quarter. increased was fiscal to sales by same-store XXX partially segment in reduction offset Same-store Our store in an in driven a sales, the end
sales, Front-end XXX XX immunizations markets growing buys gaining points core excluding execution results basis upper strong we by same-store driven on and access medication such and points basis networks market to have were new well same sales where by sales notably store pain X% in care, same respiratory, of as tobacco with personalized count cigarette strong day store due XXX as as up First Pharmacy to strong and and in file adjusted basis after a prescription adherence presence. increased interventions categories prescription to through Aid.
a credit points cost than better as revenues. million for in resulted dollars the drug a and last includes inflation. Retail generic of pharmacy quarter earlier from XXX pharmacy margin gross brand which percent gross basis quarter LIFO partially profit by mentioned the better $XX fourth quarter the and deflation drug were I Total retail segment year's gross fourth profit offset was
million as last basis profit year's points gross XX quarter than fourth year revenues. to of EBITDA by a $X.X a Adjusted prior percent was and worse favorable
EBITDA adjusted prescription improvement to profit an gross lower offset driven growth gross increasing partially in by by rates. Our pharmacy was due profit reimbursement
year's decline profit million $X to segment Retail vendor fourth front as SG&A to was The a pharmacy last the quarter. by promotional allowances. percent in lower gross of due pharmacy was profit expense flat improvement gross quarter in revenues higher end for a offset and partially
points adjusted primarily EBITDA in EBITDA increase $XX.X million income SG&A was adjusted reduced year. Walgreens. last basis worse was fee than and TSA Our driven The by SG&A XX from
in increase Part Adjusted which an million segment Our for segment EBITDA $XX.X pharmacy growth million increased our related adjusted continue pharmacy had an or Medicate Pharmacy we in was increases last of quarter partially management, Part was our revenues our $XXX D expense by in SG&A revenues to EBITDA than in revenues Elixir from D the lives. better $X.X of XX% million Services increase billion adjusted Services fourth improvements of benefited Medicare $XX.X as EBITDA Pharmacy segment to year's due membership. offset to services grow network and
compared a sale the the for statement operating source quarter. D to the prior $XXX cash cash initiatives shows in calendar to the million quarter benefited the The Part and activities $XXX quarter operating activities of cash from year the flow a year year of of result of million of of our cash from reduce Our operating in receivable use front-end from in CMS from inventory. activities current from XXXX quarter Medicare
Our approximately of of $X.X the remaining times adjusted completed sale which ratio of to cash be and net end fourth which debt center the is was from the pro Walgreens, forma of subsequent quarter proceeds our account EBITDA, year-end. X.X takes to at the impact to is distribution into expected our billion leverage balance
during secured XXXX, completed we notes to announced, which our April profile. second previously July million debt to an improves of quarter, notes XXXX As exchange of due of the lien maturity our XXX% $XXX X.X%
runway liquidity is strong Our XXXX and very execute had debt flexibility strategic until initiatives. maturing our we quarter at no to of billion $X with end the and
of and for sales of the March XX%. frontend by COVID-XX demand how increase demand of April. in discussing OTC weeks increases weeks general through moderated Before first impacted These spend saw same-store impacted guidance during in several for XXXX, the an paper minutes by revenues cleaning products me update first significant products, wipes, fiscal has XXXX. few our providing fiscal items. month business We has our increasing few a were on the with sanitizers, let a The
X.X% acceleration to this procedures days a prescriptions. delay acute on and a are could maintenance Same-store a counts risk that There month the elective phenomenon item script XX in for of timing of driven have March May. script by a this of sales. on fills as for prescriptions the impact expect We trends in negative have impact negative and is April also medical short-term view
The benefit Hayward and that increased we sales other and pay charges expense by largely have increased has investments debit center from and volume increases and bonuses fees. increased related been our credit card earlier that seen adjustments distribution and store hourly associates, as made COVID-XX for related described offset including stores managers clean pharmacists, for in to to supply store such costs
the chain, supply current supply generic good. drugs and branded of for Regarding our is majority our
However, hydroxychloroquine generic as monitoring and products. seen such supply and increased of inhalers these closely demand and products we've other for generic are the certain
mail issues our order seen impact partners D favorable utilization a products ratio others we've diligently Invision our Insurance, plan. prescriptions working the had to business. in in in in has which We've restocking increase and Offsetting is on back Elixir, on our with get impact industry. a side. at of negative of higher with supplier Medicare the our an medical to demand front-end We're similar Part this loss drug At utilization heavy
membership negative in for not have seen changes total our we clients. any far PBM So
continue monitor a closely. to is negatively we impact this could that and there PBM risk related membership extended gross will layoffs However, and margin
liquidity is and very cash strong. position Our
credit million dollars billion year additional with decline receipts have credit during end revolving billion $XXX no cash due liquidity these to $X out holding differences times. of our of is drawn our of and at expected to a payments. an from abundance the slight facility an and current on revolving caution The We've accessing had timing uncertain issue facility $X.X
not business Covid-XX the fiscal justify our does during It our the that Covid-XX XX of to the issued changing impacts At on the guidance fiscal predict is that could time, materially note XXXX and this to are XXXX we impact information results fluid on these March on Day company about of to presentation. important have difficult estimates Analyst and enough ultimate change.
prescriptions dismissing cause front-end estimates could a social reduction measures, and XXXX a a to commercial or disruptions clients, sales Pharmacy to prolong change in deterioration Services at front-end materially pharmaceutical our segment, and include our members that fiscal Factors to for due supply in chain.
for retail offset for by strong pharmacy cost reflect growth savings generic and continued assumptions the rate SG&A count segment guidance and expense Our drug pressure, partially reimbursement control. prescription expectations continued
guidance assumes Pharmacy sustained and improvements expense from and segment network initiatives. and Services activities Our pharmacy for other integration in SG&A management the benefits reduction reduction
charges Our estimated re-launch the guidance certain are well brands and also merchandise restructuring in EBITDA. retail adjusted included cost stores. Rite approximately $XX million lines These include in as not the transitioning charges assumes to which Aid of Elixir as the
$XX.X total $X.XX billion We revenues revenues be to billion $XX.X $X.XX and including expect between PBM of billion to billion.
increase of X.X%. We expect same-store of X.X% sales to be range an to in a
and $XXX million to EBITDA loss $XXX $XX million be adjusted between net be $XXX and between expected and million expect to million. We
to income net share. adjusted income between share per of expected $X.XX loss of $X.XX and be per We a
be are be and expected to $XXX XXXX fiscal will expenditures Our technology. concentrated capital on It investments million.
is Our risk and in to fiscal we plans that to construction a stores the number our will There restrictions XXXX. on governmental activity perform delay growth. file could local that rebranding and prescription in initiatives future buys out permitting of stores closures could remodels drive roll of that our new the store and sites offices impact
guidance too However early it's expenditures. to for capital update our
the of the will phone lines questions. opening portion your And with be my completes that, for now This we presentation.
